HonorStocks Biotech Gold Oil Mining China Asian MENU
Biotech Gold Oil Mining China Asian
Find Tomorrow's Winners Today

Stock technical analysis
Rating Flag Rating Flag Rating Flag Rating Flag Rating Flag
sell neutral buy
Can-Fite BioPharma Ltd. (CANF)
2  0.06  (3.09%) 07-03 15:10
Open: 1.94 High: 2.02
Pre.close: 1.94 Low: 1.91
Volume: 771,673 Ave vol: 1,206,214
52w High: 4.95 52w Low: 1.08
MA(50): 1.952 MA(200): 1.981
EPS: -3.06 P/E Ratio: 0
Company profile
Exchange: AMEX
Sector: Healthcare
Industry: Biotechnology
Website: http://www.canfite.com
Market Cap (M): 27
Shares Out (M): 14
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, and sexual dysfunction. The company's lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 (Namodenoson) that is completed Phase II clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase II trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. Can-Fite BioPharma Ltd. has collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases.
Technical analysis
Overall: Neutral
MA: Bullish MACD: Bullish
KDJ: Bullish RSI: Bullish
Target 1: 2.52 Target 2: 2.92
Resist 1: 2.16 Resist 2: 2.50
Support 1: 1.61 Support 2: 1.34
Company key metrics
Revenue per Share: 0.0237
Net Income per Share: -0.1116
Cash per Share: 0.0314
Book Value per Share: 0
Price to Sales: 91.7443
Price to Book Value: 0
Earnings Yield: -0.0514
Dividend Yield: 0
Debt to Equity: 0
Debt to Assets: 3.9059
Financial analysis
Price to Book Value: Neutral
Return on Assets: Neutral
Return on Equity: Neutral
Discounted cash flow: Neutral
Price to Earnings: Neutral
Debt to Equity: Neutral
Stock Charts
Headline news
Fri, 19 Jun 2020
Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) Receives Positive FDA opinion on IND Application For Piclidenoson in Treating COVID-19 - BP Journal

Tue, 30 Jun 2020
Can-Fite BioPharma Ltd. (AMEX:CANF) Recent Earnings Shows Major Promise - The Oracle Dispatch

Mon, 08 Jun 2020
Can-Fite Participating in BIO Digital International Convention and One-on-One Partnering Meetings on June 8-12, 2020 - Business Wire

Tue, 09 Jun 2020
Following Pre-IND Guidance from FDA Can-Fite to Advance Piclidenoson into Phase II COVID-19 Trial in the U.S. - Business Wire

Thu, 04 Jun 2020
Can-Fite Concludes Successful Meeting with European Medicines Agency (EMA) Regarding Phase III Trial and Registration Plan for Namodenoson in the Treatment of Liver Cancer - Business Wire

Tue, 30 Jun 2020
Can-Fite BioPharma (CANF) Reports Final Data Analysis from Phase II NASH Study Demonstrates Highly Significant & Sustained Reduction in Liver Fat Volume Throughout Study Period - StreetInsider.com

HonorStocks, Find Tomorrow's Winners Today

©HonorStocks.com | U.S. stock markets, stock quotes and stock analysis. Data and information is provided for informational purposes only, is not intended for trading purposes and is not investment advice. Neither HonorStocks.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Market data provided by: IEX and Financial Modeling Prep

Privacy Policy: Third parties, including Google, may be placing and reading cookies on your browsers, or other methods to collect information as a result of ad serving on this website. Google's use of advertising cookies enables it and its partners to serve ads to you based on your visit to this site and/or other sites on the Internet. You may opt out of personalized advertising by visiting Ads Settings. If you choose to use this website, you agree to the collection and use of information in relation to this policy. The information collected is used for providing and improving the ads Service. We will not use or share information with anyone, and we do not store any data from users.